Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine versus placebo in children and adolescents with major depressive disorder
2017-001598-18Phase 3
- Sponsor
- Eli Lilly and Company
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of duloxetine in major depressive disorder (MDD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from baseline in Children's Depression Rating Scale-Revised total score at Week 10 endpoint.
02
Drugs
duloxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2017-001598-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001598-18.